A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Completed · Phase 2 · NCT04166773
Conditions: Nonalcoholic Steatohepatitis
At a glance
- Research payments reported, 2025
- $24,924
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 190
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2019-11-19; completion 2024-01-10
- Results posted
- Yes
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
From ClinicalTrials.gov, last updated 2025-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $24,924 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Richard M. Glover II, MD Family Medicine · Newton, KS
- Mohammad S. Siddiqui, MD Gastroenterology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Virginia Commonwealth University $24,194
- Alliance for Multispecialty Research Lls $730
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.